Drug Pipeline

BNT316 Clinical Trials

Data updated daily from ClinicalTrials.gov — last refresh 2026-06-12
4
Active Studies
2
Recruiting
1
Phase 3
2
Top Sponsors
2
Changes, 30 Days
What Changed in the Last 30 Days
DetectedTrialChange
2026-05-23 NCT05682443
ONC-392 Plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients With mCRPC		 date change Primary completion pushed: 2026-06-30 -> 2026-11-30
2026-05-23 NCT05682443
ONC-392 Plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients With mCRPC		 date change Completion pushed: 2027-06-30 -> 2027-11-30
Active Studies by Phase
Phase 3
1
Phase 2
1
Phase 1/2
1
Phase 1
1
Active Trials
NCT IDTitleConditionStatus
Phase 3
NCT05671510 ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors Non Small Cell Lung Cancer Recruiting
Phase 2
NCT05446298 ONC-392 and Pembrolizumab in Platinum Resistant Ovarian Cancer Ovarian Cancer Active, Not Recruiting
Phase 1/2
NCT05682443 ONC-392 Plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients With mCRPC Metastatic Castration-resistant Prostate Cancer Active, Not Recruiting
Phase 1
NCT05142189 Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116… Non-Small Cell Lung Cancer Recruiting
Sponsors Running BNT316 Trials
OncoC4, Inc. (3) BioNTech SE (1)
Disease Areas
Non-Small Cell Lung Cancer (NSCLC) (2) Lung Cancer (2) Ovarian Cancer (1) Prostate Cancer (1)
Get alerts when BNT316 trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free